MX2021013268A - Nuevas capsides de aav y composiciones que las contienen. - Google Patents
Nuevas capsides de aav y composiciones que las contienen.Info
- Publication number
- MX2021013268A MX2021013268A MX2021013268A MX2021013268A MX2021013268A MX 2021013268 A MX2021013268 A MX 2021013268A MX 2021013268 A MX2021013268 A MX 2021013268A MX 2021013268 A MX2021013268 A MX 2021013268A MX 2021013268 A MX2021013268 A MX 2021013268A
- Authority
- MX
- Mexico
- Prior art keywords
- novel aav
- compositions containing
- containing same
- aav capsids
- novel
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962840184P | 2019-04-29 | 2019-04-29 | |
| US201962913314P | 2019-10-10 | 2019-10-10 | |
| US201962924095P | 2019-10-21 | 2019-10-21 | |
| PCT/US2020/030266 WO2020223231A1 (en) | 2019-04-29 | 2020-04-28 | Novel aav capsids and compositions containing same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021013268A true MX2021013268A (es) | 2021-11-17 |
Family
ID=73028724
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021013266A MX2021013266A (es) | 2019-04-29 | 2020-04-28 | Nuevas capsides de aav y composiciones que las contienen. |
| MX2021013268A MX2021013268A (es) | 2019-04-29 | 2020-04-28 | Nuevas capsides de aav y composiciones que las contienen. |
| MX2021013267A MX2021013267A (es) | 2019-04-29 | 2020-04-28 | Nuevas capsides de aav y composiciones que las contienen. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021013266A MX2021013266A (es) | 2019-04-29 | 2020-04-28 | Nuevas capsides de aav y composiciones que las contienen. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021013267A MX2021013267A (es) | 2019-04-29 | 2020-04-28 | Nuevas capsides de aav y composiciones que las contienen. |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20220249705A1 (enExample) |
| EP (3) | EP3962507A4 (enExample) |
| JP (3) | JP7690401B2 (enExample) |
| KR (3) | KR20220004681A (enExample) |
| CN (3) | CN113853207A (enExample) |
| AU (3) | AU2020264975A1 (enExample) |
| BR (3) | BR112021020054A2 (enExample) |
| CA (3) | CA3134468A1 (enExample) |
| CL (3) | CL2021002768A1 (enExample) |
| CO (3) | CO2021015916A2 (enExample) |
| IL (3) | IL287492A (enExample) |
| MX (3) | MX2021013266A (enExample) |
| PE (3) | PE20220014A1 (enExample) |
| PH (3) | PH12021552608A1 (enExample) |
| SG (3) | SG11202111102SA (enExample) |
| WO (3) | WO2020223236A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230220069A1 (en) | 2020-06-17 | 2023-07-13 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of gene therapy patients |
| EP4200429A1 (en) | 2020-08-24 | 2023-06-28 | The Trustees of The University of Pennsylvania | Viral vectors encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases |
| WO2022094078A1 (en) | 2020-10-28 | 2022-05-05 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of rett syndrome |
| CN116648448A (zh) | 2020-11-11 | 2023-08-25 | 欧洲分子生物学实验室 | 用于基因治疗的修饰病毒粒子 |
| IL303239A (en) | 2020-12-01 | 2023-07-01 | Univ Pennsylvania | Compositions and their uses for the treatment of Engelmann syndrome |
| MX2023006444A (es) | 2020-12-01 | 2023-08-10 | Univ Pennsylvania | Composiciones novedosas con motivos dirigidos a tejido específico y composiciones que los contienen. |
| AR125406A1 (es) | 2021-04-23 | 2023-07-12 | Univ Pennsylvania | Nuevas composiciones con motivos selectivos para el cerebro y composiciones que las contienen |
| EP4469584A1 (en) | 2022-01-25 | 2024-12-04 | The Trustees of The University of Pennsylvania | Aav capsids for improved heart transduction and detargeting of liver |
| IL315248A (en) * | 2022-03-01 | 2024-10-01 | Univ Pennsylvania | Viral vector genome encoding an insulin fusion protein |
| IL315251A (en) * | 2022-03-03 | 2024-10-01 | Univ Pennsylvania | Viral vectors encoding parathyroid hormone fusions and their uses for the treatment of hypoparathyroidism |
| KR20250007064A (ko) | 2022-04-06 | 2025-01-13 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Her2 양성 전이성 유방암 및 기타 암을 치료하기 위한 조성물 및 방법 |
| WO2023196892A1 (en) | 2022-04-06 | 2023-10-12 | The Trustees Of The University Of Pennsylvania | Passive immunization with anti- aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors |
| WO2024015966A2 (en) * | 2022-07-15 | 2024-01-18 | The Trustees Of The University Of Pennsylvania | Recombinant aav having aav clade d and clade e capsids and compositions containing same |
| EP4634394A2 (en) | 2022-12-17 | 2025-10-22 | The Trustees of The University of Pennsylvania | Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same |
| WO2024130070A2 (en) | 2022-12-17 | 2024-06-20 | The Trustees Of The University Of Pennsylvania | Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof |
| WO2024258961A1 (en) | 2023-06-12 | 2024-12-19 | The Trustees Of The University Of Pennsylvania | Aav gene therapy for mucopolysaccharidosis iiib |
| WO2025007046A1 (en) | 2023-06-29 | 2025-01-02 | The Trustees Of The University Of Pennsylvania | Mutant aav with central nervous system targeting motifs and compositions containing same |
| WO2025035143A1 (en) | 2023-08-10 | 2025-02-13 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of spinal muscular atrophy |
| WO2025102034A1 (en) | 2023-11-10 | 2025-05-15 | The Trustees Of The University Of Pennsylvania | Gene therapy for barth syndrome |
| WO2025106661A1 (en) | 2023-11-14 | 2025-05-22 | The Trustees Of The University Of Pennsylvania | Compositions with cardiac and skeletal musclespecific targeting motifs and uses thereof |
| GB202319008D0 (en) * | 2023-12-13 | 2024-01-24 | Ucl Business Ltd | AAV-mediated gene therapy of diseases caused by impaired function of GLDC |
| WO2025129157A1 (en) | 2023-12-15 | 2025-06-19 | The Trustees Of The University Of Pennsylvania | Gene therapy for treatment of canavan disease |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG168422A1 (en) * | 2001-11-13 | 2011-02-28 | Univ Pennsylvania | A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
| EP3910063A1 (en) * | 2003-09-30 | 2021-11-17 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor |
| EP3409296A1 (en) * | 2005-04-07 | 2018-12-05 | The Trustees of the University of Pennsylvania | Method of increasing the function of an aav vector |
| WO2006119432A2 (en) * | 2005-04-29 | 2006-11-09 | The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services | Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes |
| CN101495624A (zh) * | 2006-04-28 | 2009-07-29 | 宾夕法尼亚州立大学托管会 | 衣壳免疫原性降低的经修饰aav载体及其用途 |
| EP2012122A1 (en) * | 2007-07-06 | 2009-01-07 | Medigene AG | Mutated parvovirus structural proteins as vaccines |
| WO2010138263A2 (en) * | 2009-05-28 | 2010-12-02 | University Of Massachusetts | Novel aav 's and uses thereof |
| EP3540055A1 (en) * | 2010-04-23 | 2019-09-18 | University of Massachusetts | Cns targeting aav vectors and methods of use thereof |
| PH12016500162B1 (en) * | 2013-07-22 | 2024-02-21 | Childrens Hospital Philadelphia | Variant aav and compositions, methods and uses for gene trnsfer to cells, organs, and tissues |
| NZ758025A (en) * | 2013-10-11 | 2022-07-01 | Massachusetts Eye & Ear Infirmary | Methods of predicting ancestral virus sequences and uses thereof |
| ES2990174T3 (es) * | 2014-03-10 | 2024-11-29 | Uniqure Ip Bv | Vectores de AAV mejorados producidos en células de insecto |
| EP3151866B1 (en) * | 2014-06-09 | 2023-03-08 | Voyager Therapeutics, Inc. | Chimeric capsids |
| RU2738421C2 (ru) * | 2014-10-21 | 2020-12-14 | Юниверсити Оф Массачусетс | Варианты рекомбинантных aav и их применения |
| AU2015349759B2 (en) * | 2014-11-21 | 2022-01-06 | The University Of North Carolina At Chapel Hill | Aav vectors targeted to the central nervous system |
| EP3233131A1 (en) * | 2014-12-16 | 2017-10-25 | Board of Regents of the University of Nebraska | Gene therapy for juvenile batten disease |
| MX2017009336A (es) * | 2015-01-16 | 2017-11-15 | Voyager Therapeutics Inc | Polinucleótidos dirigidos al sistema nervioso central. |
| CA2994160C (en) * | 2015-07-30 | 2021-08-10 | Massachusetts Eye And Ear Infirmary | Ancestral virus sequences and uses thereof |
| EP3368054A4 (en) * | 2015-10-28 | 2019-07-03 | Voyager Therapeutics, Inc. | REGULATORY EXPRESSION USING THE ADENO-ASSOCIATED VIRUS (AAV) |
| HK1258413A1 (zh) * | 2015-10-29 | 2019-11-08 | Voyager Therapeutics, Inc. | 遞送中樞神經系統(cns)靶向多核苷酸 |
| EP3448874A4 (en) * | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| CA3024448C (en) * | 2016-05-18 | 2025-09-09 | Voyager Therapeutics, Inc. | MODULATING POLYNUCLEOTIDES |
| EP3528785A4 (en) * | 2016-10-19 | 2020-12-02 | Adverum Biotechnologies, Inc. | MODIFIED AAV CASPIDS AND USES THEREOF |
| US11827906B2 (en) * | 2017-02-28 | 2023-11-28 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) clade f vector and uses therefor |
| CN110770346B (zh) * | 2017-03-15 | 2024-01-12 | 北卡罗来纳-查佩尔山大学 | 多倍体腺相关病毒载体及其制备和使用方法 |
| US10550405B2 (en) * | 2017-03-15 | 2020-02-04 | The University Of North Carolina At Chapel Hill | Rational polyploid adeno-associated virus vectors and methods of making and using the same |
| WO2018200419A1 (en) * | 2017-04-23 | 2018-11-01 | The Trustees Of The University Of Pennsylvania | Viral vectors comprising engineered aav capsids and compositions containing the same |
| JOP20190269A1 (ar) * | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| EP3662060A2 (en) * | 2017-08-03 | 2020-06-10 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
-
2020
- 2020-04-28 WO PCT/US2020/030281 patent/WO2020223236A1/en not_active Ceased
- 2020-04-28 SG SG11202111102SA patent/SG11202111102SA/en unknown
- 2020-04-28 KR KR1020217037661A patent/KR20220004681A/ko active Pending
- 2020-04-28 MX MX2021013266A patent/MX2021013266A/es unknown
- 2020-04-28 EP EP20798753.8A patent/EP3962507A4/en not_active Withdrawn
- 2020-04-28 US US17/605,881 patent/US20220249705A1/en not_active Abandoned
- 2020-04-28 KR KR1020217037659A patent/KR20220004680A/ko not_active Withdrawn
- 2020-04-28 CN CN202080032666.9A patent/CN113853207A/zh active Pending
- 2020-04-28 PE PE2021001788A patent/PE20220014A1/es unknown
- 2020-04-28 PH PH1/2021/552608A patent/PH12021552608A1/en unknown
- 2020-04-28 SG SG11202111373YA patent/SG11202111373YA/en unknown
- 2020-04-28 WO PCT/US2020/030273 patent/WO2020223232A1/en not_active Ceased
- 2020-04-28 JP JP2021564269A patent/JP7690401B2/ja active Active
- 2020-04-28 CA CA3134468A patent/CA3134468A1/en active Pending
- 2020-04-28 US US17/605,874 patent/US20220220453A1/en active Pending
- 2020-04-28 CN CN202080033196.8A patent/CN113853209B/zh active Active
- 2020-04-28 BR BR112021020054A patent/BR112021020054A2/pt unknown
- 2020-04-28 JP JP2021564543A patent/JP2022530656A/ja active Pending
- 2020-04-28 AU AU2020264975A patent/AU2020264975A1/en active Pending
- 2020-04-28 JP JP2021564542A patent/JP7644026B2/ja active Active
- 2020-04-28 US US17/605,868 patent/US20220204990A1/en active Pending
- 2020-04-28 CA CA3134507A patent/CA3134507A1/en active Pending
- 2020-04-28 EP EP20798442.8A patent/EP3976077A4/en active Pending
- 2020-04-28 AU AU2020266523A patent/AU2020266523A1/en active Pending
- 2020-04-28 PH PH1/2021/552540A patent/PH12021552540A1/en unknown
- 2020-04-28 WO PCT/US2020/030266 patent/WO2020223231A1/en not_active Ceased
- 2020-04-28 BR BR112021021502A patent/BR112021021502A2/pt unknown
- 2020-04-28 PH PH1/2021/552607A patent/PH12021552607A1/en unknown
- 2020-04-28 AU AU2020264976A patent/AU2020264976A1/en active Pending
- 2020-04-28 CA CA3134379A patent/CA3134379A1/en active Pending
- 2020-04-28 KR KR1020217038207A patent/KR20220004695A/ko active Pending
- 2020-04-28 MX MX2021013268A patent/MX2021013268A/es unknown
- 2020-04-28 MX MX2021013267A patent/MX2021013267A/es unknown
- 2020-04-28 BR BR112021020545A patent/BR112021020545A2/pt unknown
- 2020-04-28 PE PE2021001795A patent/PE20212267A1/es unknown
- 2020-04-28 CN CN202080032773.1A patent/CN113853208A/zh active Pending
- 2020-04-28 PE PE2021001789A patent/PE20212334A1/es unknown
- 2020-04-28 SG SG11202111375RA patent/SG11202111375RA/en unknown
- 2020-04-28 EP EP20798752.0A patent/EP3976078A4/en active Pending
-
2021
- 2021-10-21 IL IL287492A patent/IL287492A/en unknown
- 2021-10-21 CL CL2021002768A patent/CL2021002768A1/es unknown
- 2021-10-21 IL IL287491A patent/IL287491A/en unknown
- 2021-10-21 IL IL287498A patent/IL287498A/en unknown
- 2021-10-26 CL CL2021002811A patent/CL2021002811A1/es unknown
- 2021-10-27 CL CL2021002824A patent/CL2021002824A1/es unknown
- 2021-11-25 CO CONC2021/0015916A patent/CO2021015916A2/es unknown
- 2021-11-25 CO CONC2021/0015928A patent/CO2021015928A2/es unknown
- 2021-11-25 CO CONC2021/0015924A patent/CO2021015924A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021002811A1 (es) | Nuevas cápsides de aav y composiciones que las contienen. | |
| MX2023001863A (es) | Nuevas cápsides de aav y composiciones que las contienen. | |
| DK3964969T3 (da) | Opdeling af soc-arkitektur | |
| MX2021014728A (es) | Composiciones terapeuticas que comprenden compuestos n,n-dimetiltriptamina deuterada o parcialmente deuterada. | |
| CL2019000167A1 (es) | Novedosas proteínas de la cápside del virus adenoasociado. | |
| MX2023012722A (es) | Capsides de aav y usos de las mismas. | |
| PE20210113A1 (es) | Nuevos vectores virales adeno-asociados dirigidos al higado | |
| PE20190129A1 (es) | Capsides variantes de virus adenoasociados y metodos de uso de estas | |
| MX2019009720A (es) | Metodos y composiciones para la transferencia de genes a traves de la vasculatura. | |
| AR113490A1 (es) | CONSTRUCCIONES DE ARNi PARA INHIBIR LA EXPRESIÓN DE PNPLA3 Y MÉTODOS DE USO DE LAS MISMAS | |
| CL2023001793A1 (es) | Anticuerpos anti-componente de complemento y métodos de uso | |
| CO2019009612A2 (es) | Proteinas de unión a antígeno anti-tigit y métodos de uso de las mismas | |
| ECSP22027871A (es) | COMPUESTOS HETEROC?CLICOS DE ARILMETILENO COMO BLOQUEADORES DEL CANAL SHAKER DE POTASIO Kv1.3 | |
| UY38733A (es) | Construcciones de arni para inhibir la expresión de scap y métodos de uso de las mismas | |
| MX2022001449A (es) | Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos. | |
| UY37376A (es) | Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso | |
| UY37863A (es) | Virus adenoasociado (aav) con dominio de fosfolipasa modificado | |
| EP4019642A4 (en) | ISOLATED MODIFIED VP1 CAPSID PROTEIN FROM AAV5 | |
| EP4536168A4 (en) | MEDICAL ADMINISTRATION SET | |
| EP4387641A4 (en) | RECOMBINANT AAV FORMULATIONS | |
| NZ759802A (en) | Rational polyploid adeno-associated virus vectors and methods of making and using the same | |
| AR120259A1 (es) | Variantes de aav3b con rendimiento mejorado de la producción y tropismo hepático | |
| MX2024009186A (es) | Cápsides de aav para mejorar la transducción cardiaca y desdireccionamiento del hígado. | |
| EA202192955A1 (ru) | Новые капсиды aav и композиции, содержащие их | |
| EP3984549A4 (en) | Medicinal composition |